Molecular Partners (MOLN) News Today $3.91 +0.01 (+0.26%) Closing price 03/25/2025 02:24 PM EasternExtended Trading$3.94 +0.03 (+0.77%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Molecular Partners to hold three poster presentations at AACR 2025March 25 at 4:00 PM | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2025March 25 at 12:00 PM | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)March 17, 2025 | markets.businessinsider.comMolecular Partners (MOLN) Initiated with a Buy at LifeSci CapitalMarch 15, 2025 | markets.businessinsider.comMolecular Partners (NASDAQ:MOLN) Coverage Initiated by Analysts at Lifesci CapitalLifesci Capital began coverage on shares of Molecular Partners in a research note on Tuesday. They issued an "outperform" rating and a $12.00 price target on the stock.March 12, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform RecommendationMarch 12, 2025 | msn.comMolecular Partners initiated with an Outperform at LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comMolecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comFY2024 Earnings Estimate for MOLN Issued By Leerink PartnrsMolecular Partners AG (NASDAQ:MOLN - Free Report) - Stock analysts at Leerink Partnrs issued their FY2024 earnings estimates for Molecular Partners in a note issued to investors on Thursday, March 6th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($1.93) per shaMarch 10, 2025 | marketbeat.comMolecular Partners Full Year 2024 Earnings: CHF1.59 loss per share (vs CHF1.89 loss in FY 2023)March 9, 2025 | finance.yahoo.comMolecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...March 8, 2025 | gurufocus.comFull Year 2024 Molecular Partners AG Earnings Call TranscriptMarch 8, 2025 | gurufocus.comMolecular Partners AG: Strategic Advances and Financial OverviewMarch 7, 2025 | tipranks.comMolecular Partners (NASDAQ:MOLN) Releases Earnings Results, Beats Estimates By $0.11 EPSMolecular Partners (NASDAQ:MOLN - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%.March 7, 2025 | marketbeat.comMolecular Partners AG (MOLN) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comMolecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024March 6, 2025 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Trading 0.3% Higher - What's Next?Molecular Partners (NASDAQ:MOLN) Stock Price Up 0.3% - Should You Buy?March 1, 2025 | marketbeat.comMolecular Partners (MOLN) Expected to Announce Quarterly Earnings on ThursdayMolecular Partners (NASDAQ:MOLN) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671807)March 1, 2025 | marketbeat.comMolecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference CallFebruary 28, 2025 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 0.2% - Time to Sell?Molecular Partners (NASDAQ:MOLN) Shares Down 0.2% - Here's WhyFebruary 6, 2025 | marketbeat.comInvestors in Molecular Partners (VTX:MOLN) have unfortunately lost 81% over the last three yearsJanuary 28, 2025 | finance.yahoo.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 0.6% - What's Next?Molecular Partners (NASDAQ:MOLN) Trading Down 0.6% - Here's WhyJanuary 15, 2025 | marketbeat.comMolecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2025 | globenewswire.comMolecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancerJanuary 12, 2025 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Stock Price Up 7.1% - Here's What HappenedMolecular Partners (NASDAQ:MOLN) Stock Price Up 7.1% - What's Next?December 24, 2024 | marketbeat.comMolecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in JanuaryDecember 17, 2024 | globenewswire.comMolecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024December 8, 2024 | globenewswire.comMolecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024November 7, 2024 | globenewswire.comMolecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and ExpositionNovember 6, 2024 | markets.businessinsider.comMolecular Partners’ Promising Pipeline and Financial Stability Justify Buy RatingNovember 5, 2024 | markets.businessinsider.comMolecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-goingOctober 31, 2024 | globenewswire.comMolecular Partners Announces Pricing of $20 Million Underwritten OfferingOctober 25, 2024 | globenewswire.comMolecular Partners, Orano Med announce presentation of MP0712 dataOctober 22, 2024 | markets.businessinsider.comMolecular Partners stock climbs 6% on expanded radiopharmaceuticals dealOctober 22, 2024 | msn.comMolecular Partners Expands Agreement With Orano Med for Cancer TreatmentOctober 22, 2024 | marketwatch.comMolecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin TherapeuticsOctober 22, 2024 | finance.yahoo.comMolecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin TherapeuticsOctober 22, 2024 | globenewswire.comMolecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024October 22, 2024 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Stock, Short Interest ReportOctober 22, 2024 | benzinga.comEquities Analysts Issue Forecasts for Molecular Partners AG's Q3 2024 Earnings (NASDAQ:MOLN)Molecular Partners AG (NASDAQ:MOLN - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for Molecular Partners in a report issued on Monday, October 7th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.63) forOctober 9, 2024 | marketbeat.comMolecular Partners (NASDAQ:MOLN) Upgraded to Strong-Buy by Leerink PartnrsLeerink Partnrs raised Molecular Partners to a "strong-buy" rating in a research note on Monday.October 8, 2024 | marketbeat.comMolecular Partners Announces upcoming poster presentations at the 2024 SITC Annual MeetingOctober 4, 2024 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 1.9%Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.9%October 3, 2024 | marketbeat.comMolecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024September 27, 2024 | globenewswire.comIs Molecular Partners (VTX:MOLN) In A Good Position To Deliver On Growth Plans?September 25, 2024 | finance.yahoo.comImmunoPrecise Antibodies Ltd. (TQB.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comGenfit S.A. (XUP.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 0.3%Molecular Partners (NASDAQ:MOLN) Trading Down 0.3%September 11, 2024 | marketbeat.comMolecular Partners AG: Hold Rating with Adjusted Price Target Amidst Development Delays and Financial UncertaintiesAugust 29, 2024 | markets.businessinsider.comMolecular Partners Reports H1 2024 Corporate Highlights and FinancialsAugust 26, 2024 | globenewswire.com Remove Ads Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address MOLN Media Mentions By Week MOLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOLN News Sentiment▼0.000.79▲Average Medical News Sentiment MOLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOLN Articles This Week▼31▲MOLN Articles Average Week Remove Ads Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LENZ Therapeutics News Today CorMedix News Today Sionna Therapeutics News Today Organogenesis News Today Arbutus Biopharma News Today Sana Biotechnology News Today KalVista Pharmaceuticals News Today MeiraGTx News Today ChromaDex News Today Pharming Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MOLN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
